{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-000338","form_type":"8-K","ticker":"IVF","cik":"0001417926","company_name":"INVO Fertility, Inc.","filed_at":"2024-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.125507+00:00","generated_at":"2026-06-07T04:35:28.121891+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"INVO Bioscience extends merger deadline, secures $5M financing from NAYA, extends convertible notes","bullets":["Second Amendment extends merger end date to April 30, 2024; interim PIPE reduced to $2M of preferred stock at $5/share with schedule.","NAYA agrees to purchase up to 1M Series A Preferred shares at $5/share for $5M total, with tranches starting Dec 2023.","Convertible notes ($410k) maturity extended to June 30, 2024; conversion and warrant exercise prices reduced to $2.25.","CEO and CFO salary temporarily reduced to $105k from Aug 2023; reverted to $260k and $215k on Jan 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-000338","json":"https://secwatch.observer/filing/0001493152-24-000338.json","markdown":"https://secwatch.observer/filing/0001493152-24-000338.md","text":"https://secwatch.observer/filing/0001493152-24-000338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224000338/0001493152-24-000338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224000338/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:35:28.121891+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2ef930c743de66cb5c721411df945e07fddcb5bb","claim":"INVO Fertility, Inc. amended Convertible Notes Extension with Required Holders of Convertible Notes valued at Maturity date extended to June 30, 2024; conversion and warrant exercise price lowered to $2.25 (effective 2023-12-27).","evidence_excerpt":"As of December 27, 2023, the Company secured written consent by the Required Holders for the Convertible Note maturity date to be extended to June 30, 2024.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224000338/0001493152-24-000338-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Required Holders of Convertible Notes"},{"label":"Value","value":"Maturity date extended to June 30, 2024; conversion and warrant exercise price lowered to $2.25"},{"label":"Effective","value":"2023-12-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}